MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 02.03.2026
Cerus Corporation EV 2011-2026 | CERS
EV Jährlich Cerus Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 632 M | 425 M | 488 M | 571 M | 1.27 B | 1.21 B | 657 M | 803 M | 561 M | 443 M | 495 M | 417 M | 435 M | 174 M | 134 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.27 B | 134 M | 581 M |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
11.8 B | $ 7.72 | 1.85 % | $ 6.83 B |  Spain |
 |
Amphastar Pharmaceuticals
AMPH
|
1.92 B | $ 19.68 | 0.92 % | $ 920 M |  USA |
 |
Amarin Corporation plc
AMRN
|
5.88 B | $ 14.5 | 0.03 % | $ 6.02 B |  Irlanda |
 |
GlaxoSmithKline plc
GSK
|
41.8 B | $ 52.37 | 1.02 % | $ 173 B |  Britain |
 |
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
849 M | $ 221.59 | -0.13 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | France |
 |
Autolus Therapeutics plc
AUTL
|
1.11 B | $ 1.39 | 1.46 % | $ 355 M | Britain |
 |
Midatech Pharma plc
MTP
|
4.79 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.52 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
6.28 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
33.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
Heron Therapeutics
HRTX
|
411 M | $ 0.81 | 3.74 % | $ 135 M | USA |
 |
Avenue Therapeutics
ATXI
|
-1.23 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M |  Israel |
 |
Benitec Biopharma
BNTC
|
461 M | $ 11.05 | 0.64 % | $ 455 M | USA |
 |
Atreca
BCEL
|
94.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
445 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
916 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
71.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
91.4 M | - | - | $ 3.74 B | USA |
 |
Immunovant
IMVT
|
1.61 B | $ 24.1 | 4.85 % | $ 3.65 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
77.1 M | - | -74.18 % | $ 955 K | USA |
 |
Incyte Corporation
INCY
|
18.2 B | $ 90.36 | -0.47 % | $ 17.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
-5.18 M | $ 0.74 | -9.75 % | $ 1.81 M | Canada |
 |
INmune Bio
INMB
|
194 M | $ 1.17 | -0.43 % | $ 21 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
174 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
839 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
291 M | $ 2.13 | 1.91 % | $ 199 M | Israel |
 |
Innate Pharma S.A.
IPHA
|
259 M | $ 1.35 | 15.38 % | $ 235 M | France |
 |
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
457 M | $ 4.43 | 4.6 % | $ 735 M | Canada |
 |
Inventiva S.A.
IVA
|
129 M | $ 6.1 | 5.5 % | $ 138 M | France |
 |
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | USA |